Clinical Trial Update: A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 1 trial of CIMAvax-EGF for prevention of lung cancer development or recurrence has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Non-small Cell Lung Cancer
• Pneumonia

Drugs mentioned

• CIMAvax-EGF (EGF-depleting vaccine CIMAvax-EGF)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma | EARLY_Phase 1 | Status: COMPLETED